Diabetes is a long-lasting and serious disease that effect in worldwide individual lives, families, and societies. Hyperglycemia of diabetes mellitus produced Advance Glycation End Products that are associated with diabetic complications like neuropathy, nephropathy, retinopathy, and cardiovascular diseases. In this study, the natural products isolated from of Indigofera heterantha Brandis, Indigoferin A (S1), Indigoferin B (S2) and Indigoferin C (S3) were evaluated for their in vitro antiglycation activity. The compounds exhibited a significant inhibitory activity against the formation of Advanced Glycation End-Products with IC50 values of 674.25 ± 3.2 μM, 407.03 ± 4.7 μM and 726.41 ± 2.1 μM, respectively. Here, important structure-activity relationship was observed, when the intramolecular hydrogen bonding interactions suppressed the antiglycation activity of compound S3. Thus, the study clearly demonstrates that the number and the position of substituents act as an assisting factor and directly influence the inhibitory activity of the natural product by altering the sugar or protein binding affinity. This study explain first time the antiglycation inhibitory ability of chemical constituents isolated from I. heterantha and can be used for above late diabetic complications.

中文翻译：

---

Indigoferin一个的抗糖化电位，Indigoferin B和Indigoferin C NATURAL产品来自异花木蓝布兰迪斯

糖尿病是一种长期存在的严重疾病，会影响全世界的个人生活，家庭和社会。糖尿病的高血糖产生了糖基化终末产物，该糖基终产物与糖尿病并发症如神经病，肾病，视网膜病和心血管疾病有关。在这项研究中，评估了从Indigofera heterantha Brandis，Indigoferin A（S1），Indigoferin B（S2）和Indigoferin C（S3）分离得到的天然产物的体外抗糖化活性。这些化合物对高级糖基化终产物的形成表现出显着的抑制活性，IC50值分别为674.25±3.2μM，407.03±4.7μM和726.41±2.1μM。在这里，观察到重要的构效关系，当分子内氢键相互作用抑制化合物S3的抗糖化活性时。因此，该研究清楚地表明，取代基的数量和位置起辅助作用，并通过改变糖或蛋白质的结合亲和力直接影响天然产物的抑制活性。这项研究首次解释了从杂种鸢尾中分离出的化学成分的抗糖化抑制能力，并且可以用于上述晚期糖尿病并发症。